

Dear Esteemed Shareholders Jamjoom Pharmaceutical Factory Company
Greetings,

Notification from the Board of Directors to the General Assembly of Shareholders on the transactions with related parties

In accordance with the requirements of Article 71 of the Companies Law issued by Royal Decree No. M/132 dated 1/12/1443 AH, which includes that a member of the Board of Directors, upon becoming aware of any interest he has, whether directly or indirectly, in the business and contracts that are for the company's account, must inform the Board of this and this notification shall be recorded in the minutes of the Board meeting at its meeting, and this member may not participate in voting on the resolution issued in this regard in the Board and the General Assemblies. The Board shall inform the General Assembly upon its convening of the transactions and contracts in which the Board member has a direct or indirect interest, and shall attach to the report a special report from the Company's auditor prepared in accordance with the auditing standards adopted in the Kingdom.

Accordingly, we would like to inform the General Assembly of the following:

Transactions and contracts in which members of the Board of Directors of Jamjoom Pharmaceutical Factory have a direct or indirect interest:

- 1- The contracts and dealings conducted between the Company and Jamjoom Printing Establishment, in which Board Member Mr. Yousuf Mohammed Salah Jamjoom has a direct interest as the sole owner, while Mr. Mohammed Yousuf Jamjoom, Mr. Ahmed Yousuf Jamjoom, Mr. Mahmoud Yousuf Jamjoom, and Ms. Alaa Yousuf Jamjoom have an indirect interest. This includes providing printing services, particularly packaging materials (publications), under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 7,424,023 Saudi Riyals.
- 2- The contracts and dealings conducted between the Company and Jamjoom Medicine Store, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board, Mr. Ahmed Yousuf Jamjoom, and Board Members Mr. Mohammed Yousuf Jamjoom and Ms. Alaa Yousuf Jamjoom have a direct interest, and the Board Member Mr. Yousuf Mohammed Salah Jamjoom has an indirect interest. This involves a distribution agreement for pharmaceutical products to be distributed to customers under prevailing commercial terms without preferential benefits, noting that the contractual transaction value for the year 2023 amounted to 609,295,532 Saudi Riyals.
- 3- The contracts and dealings conducted between the Company and Jamjoom Medicine Store, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board, Mr. Ahmed Yousuf Jamjoom, and Board Members Mr. Mohammed Yousuf Jamjoom and Ms. Alaa Yousuf Jamjoom have a direct interest, and the Board Member Mr. Yousuf Mohammed Salah Jamjoom has an indirect interest. This pertains to the distribution commission based on the distribution agreement for pharmaceutical products to be distributed to customers without preferential benefits, noting that the distribution commission value for the year 2023 amounted to 3,146,333 Saudi Riyals related.
- 4- The contracts and dealings conducted between the Company and Jamjoom General Agencies, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board, Mr. Ahmed Yousuf

شركة مساهمة - رأس المال ٧٠٠ مليون ريال، س.ت. ١٥٤٥٩٦-٤٠٣٠

عنوان المصنع : رقم القطعة م. ي ١ : ٣، المنطقة الصناعية، المرحلة الخامسة، جدة . ت : ٩٦٦ ١٢ ٦٠٨ ١١١١ ، ف : ٩٦٦ ١٢ ٦٠٨ ١٢٢٢
العنوان البريدي : ٦٢٦٧، جدة - ٢١٤٤٢، المملكة العربية السعودية، الإدارة : ت : ٩٦٦ ١٢ ٦١٤ ٠٠٩٩ ، ف : ٩٦٦ ١٢ ٦١٤ ٠٠٨٨

Joint Stock Company - Capital SR. 700 Million, C.R. 4030154596

Factory Address: Plot No. ME1 : 3, Phase V, Industrial City, Jeddah, Tel.: + 966 12 608 1111, Fax: + 966 12 608 1222
Postal Address P.O.Box 6267, Jeddah 21442 Saudi Arabia, Administration: T: + 966 12 614 0099, Fax: + 966 12 614 0088
E-mail: jpharma@jamjoompharma.com - Website: www.jamjoompharma.com

شركة مصنع جمجوم للأدوية
Jamjoom Pharmaceuticals Factory Co.



Jamjoom, and Board Members Mr. Mohammed Yousuf Jamjoom and Ms. Alaa Yousuf Jamjoom have a direct interest in. While the board member Mr. Yousuf Mohammed Salah Jamjoom, has an indirect interest. This involves procuring brand reminder items under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 444,515 Saudi Riyals.

- 5- The contracts and dealings conducted between the Company and Tegan Al-Fateh Factory Company Limited, in which Board Member Mr. Yousuf Mohammed Salah Jamjoom has an indirect interest. This involves an agreement to provide printing services (small cardboard boxes for medicines) under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 20,529,024 Saudi Riyals.
- 6- The contracts and dealings conducted between the Company and Dream Sky Travel and Tourism Agency, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom has an indirect interest. This involves providing travel booking services under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 11,244,436 Saudi Riyals.
- 7- The contracts and dealings that will be conducted between the Company and Dream Sky Travel and Tourism Agency, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom has an indirect interest. This involves providing advance payments for travel booking services under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 4,553,644 Saudi Riyals as an advance payment for transaction for the year 2024.
- 8- The transactions and contracts that took place between the Company and Jamjoom Algeria Lidawa, in which the Chairman of the Board Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board Mr. Ahmed Yousuf Jamjoom, and the Board Member, Mr. Mohammed Yousuf Jamjoom, have an indirect interest. These transactions are for the purpose of operational expenses for the joint venture, under prevailing commercial terms and without preferential benefits, noting that the value of expenses for the year 2023 amounted to 821,147 Saudi Riyals.

We assure shareholders that the transaction amounts described in this notification have been reviewed and approved by the CEO, Chief Financial Officer as well as members of the Board of Directors, and we assure shareholders that all such transactions have been recorded and disclosed in the Company's financial statements for the financial year ended 31 December 2023 in accordance with the requirements of the International Financial Reporting Standards adopted in the Kingdom of Saudi Arabia.

Please accept my sincere greetings and appreciation

For and on behalf of the Board of Directors

The Chairman

29/4/2024